Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2020

Nov 12, 2020

30198_dirs_2020-11-12_052cfbd5-37ce-497f-a0bc-8d52f29f615b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2020-11-10

Reporting Person: Sylvain Jereme M (SVP, Finance & CAO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-11-10 Common Stock S 632 $336.2207 Disposed 11900 Direct

Footnotes

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: This transaction was executed in multiple trades at prices ranging from $336.2100 to $336.8834. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3: Included in this number are 9,169 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 2,412 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021.